Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Metformin (The Miracle Drug) Kinetics in Different Diseases such as Cancer

Author(s): Zahra Tolou-Ghamari*

Volume 20, Issue 6, 2024

Published on: 21 November, 2023

Page: [546 - 554] Pages: 9

DOI: 10.2174/0115733947257347231025111224

Price: $65

Abstract

Metformin, a miracle drug that was introduced a century ago, could be considered for various aspects of diseases such as diabetes (type 1 and 2), cancer prevention or chemotherapy, metabolic and neurodegenerative disease. It is well known that the frequency of cancer is higher in patients with type 2 diabetes mellitus. This review aims to provide updated information regarding clinical pharmacokinetics and the mechanism of action of Metformin in different diseases such as cancer. Diabetes type 1 is another chronic autoimmune disease detected usually in early childhood due to immune-mediated devastation of insulin-producing pancreatic beta-cells. Because of the lack of effective therapeutic approaches, its prevalence is increasing. Regarding cancer, an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths were reported in 2020 worldwide. By 50-60% bioavailability, the main route of metformin excretion is through urine. Its mechanism of action is based on 1) initiation of adenosine monophosphate-activated kinase, 2) block proinflammatory paths in perivascular adipose tissue, 3) decrease in monocyte-to-macrophage differentiation in vascular tissues, and 4) improvement in endothelial function. Metformin induces adenosine monophosphate-activated protein kinase signaling and suppresses gluconeogenesis. Antitumor properties of Metformin include a decrease in reactive oxygen species generation and inducing autophagy. In addition to glucose-lowering effects, Metformin has moderate anti-inflammatory and antioxidative effects. It could improve lipid profile and reduce overweight individuals' body mass and arterial blood pressure. In type 1 diabetes, Metformin reduces the requirement for daily insulin and improves glycemia. Its long-term use decreases cardiovascular events. In addition to inhibiting the synthesis of lipids via a reduction in oxidative stress, Metformin inhibits inflammation and increases energy metabolism. Finally, by reducing micro- and macro-vascular consequences, mortality-related diabetes and cancer decline by metformin administration. Therefore, in addition to diabetes, Metformin could reduce the proliferation of cancer cells and the possibility of malignancies in different types of cancer.

« Previous Next »
Graphical Abstract

[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 2021; 71(3): 209-49.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Thomas I, Gregg B. Metformin; A review of its history and future: From lilac to longevity. Pediatr Diabetes 2017; 18(1): 10-6.
[http://dx.doi.org/10.1111/pedi.12473] [PMID: 28052534]
[3]
Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011; 50(2): 81-98.
[http://dx.doi.org/10.2165/11534750-000000000-00000] [PMID: 21241070]
[4]
Anila K. Metformin inhibits gluconeogenesis by a redox-dependent mechanism in vivo. Nat Med 2019.
[5]
Love KM, Barrett EJ, Horton WB. Metformin’s impact on the microvascular response to insulin. Endocrinology 2022; 163(11): bqac162.
[http://dx.doi.org/10.1210/endocr/bqac162] [PMID: 36201598]
[6]
Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M, Schwab M. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS One 2011; 6(7): e22163.
[http://dx.doi.org/10.1371/journal.pone.0022163] [PMID: 21779389]
[7]
LaMoia TE, Shulman GI. Cellular and molecular mechanisms of metformin action. Endocr Rev 2021; 42(1): 77-96.
[http://dx.doi.org/10.1210/endrev/bnaa023] [PMID: 32897388]
[8]
Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med 2015; 66(1): 17-29.
[http://dx.doi.org/10.1146/annurev-med-062613-093128] [PMID: 25386929]
[9]
Werner H, Laron Z. Role of the GH-IGF1 system in progression of cancer. Mol Cell Endocrinol 2020; 518: 111003.
[http://dx.doi.org/10.1016/j.mce.2020.111003] [PMID: 32919021]
[10]
Mallik R, Chowdhury TA. Metformin in cancer. Diabetes Res Clin Pract 2018; 143: 409-19.
[http://dx.doi.org/10.1016/j.diabres.2018.05.023] [PMID: 29807101]
[11]
Sanchez-Rangel E, Inzucchi SE. Metformin: Clinical use in type 2 diabetes. Diabetologia 2017; 60(9): 1586-93.
[http://dx.doi.org/10.1007/s00125-017-4336-x] [PMID: 28770321]
[12]
Rewers M, Hyöty H, Lernmark Å, et al. The environmental determinants of diabetes in the young (TEDDY) study: 2018 update. Curr Diab Rep 2018; 18(12): 136.
[http://dx.doi.org/10.1007/s11892-018-1113-2] [PMID: 30353256]
[13]
Li J, Zhang B, Liu WX, et al. Metformin limits osteoarthritis development and progression through activation of AMPK signalling. Ann Rheum Dis 2020; 79(5): 635-45.
[http://dx.doi.org/10.1136/annrheumdis-2019-216713] [PMID: 32156705]
[14]
Ahmadi S, Razazan A, Nagpal R, et al. Metformin reduces aging related leaky gut and improves cognitive function by beneficially modulating gut microbiome/goblet cell/mucin axis. J Gerontol A Biol Sci Med Sci 2020; 75(7): e9-e21.
[http://dx.doi.org/10.1093/gerona/glaa056] [PMID: 32129462]
[15]
Taslimi S, Esteghamati A, Rashidi A, Tavakkoli HM, Nakhjavani M, Kebriaee-Zadeh A. Treatment with pioglitazone is associated with decreased preprandial ghrelin levels: A randomized clinical trial. Peptides 2013; 40: 89-92.
[http://dx.doi.org/10.1016/j.peptides.2012.12.020] [PMID: 23276779]
[16]
Chiang JL, Maahs DM, Garvey KC, et al. Type 1 diabetes in children and adolescents: A position statement by the american diabetes association. Diabetes Care 2018; 41(9): 2026-44.
[http://dx.doi.org/10.2337/dci18-0023] [PMID: 30093549]
[17]
Beysel S, Unsal IO, Kizilgul M, Caliskan M, Ucan B, Cakal E. The effects of metformin in type 1 diabetes mellitus. BMC Endocr Disord 2018; 18(1): 1.
[http://dx.doi.org/10.1186/s12902-017-0228-9] [PMID: 29338714]
[18]
Wilmot EG, Choudhary P, Leelarathna L, Baxter M. Glycaemic variability: The under‐recognized therapeutic target in type 1 diabetes care. Diabetes Obes Metab 2019; 21(12): 2599-608.
[http://dx.doi.org/10.1111/dom.13842] [PMID: 31364268]
[19]
Livingstone R, Boyle JG, Petrie JR. A new perspective on metformin therapy in type 1 diabetes. Diabetologia 2017; 60(9): 1594-600.
[http://dx.doi.org/10.1007/s00125-017-4364-6] [PMID: 28770327]
[20]
Staels F, Moyson C, Mathieu C. Metformin as add-on to intensive insulin therapy in type 1 diabetes mellitus. Diabetes Obes Metab 2017; 19(10): 1463-7.
[http://dx.doi.org/10.1111/dom.12948] [PMID: 28318105]
[21]
Sawa A, Abe T, Omoto M, Fujihara K, Kobayashi H, Tokuda Y. Lactic acidosis with metformin use in a patient with type 1 diabetes mellitus. Gen Med 2013; 14(1): 72-5.
[http://dx.doi.org/10.14442/general.14.72]
[22]
Naderpoor N, Shorakae S, de Courten B, Misso ML, Moran LJ, Teede HJ. Metformin and lifestyle modification in polycystic ovary syndrome: Systematic review and meta-analysis. Hum Reprod Update 2015; 21(5): 560-74.
[http://dx.doi.org/10.1093/humupd/dmv025] [PMID: 26060208]
[23]
Fruzzetti F, Perini D, Russo M, Bucci F, Gadducci A. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol 2017; 33(1): 39-42.
[http://dx.doi.org/10.1080/09513590.2016.1236078] [PMID: 27808588]
[24]
Lan WH, Lin TY, Yeh JA, et al. Mechanism underlying metformin action and its potential to reduce gastric cancer risk. Int J Mol Sci 2022; 23(22): 14163.
[http://dx.doi.org/10.3390/ijms232214163] [PMID: 36430639]
[25]
Mostafavi S, Zalpoor H, Hassan ZM. The promising therapeutic effects of metformin on metabolic reprogramming of cancer associated fibroblasts in solid tumors. Cell Mol Biol Lett 2022; 27(1): 58.
[http://dx.doi.org/10.1186/s11658-022-00356-2] [PMID: 35869449]
[26]
Zhang Q, Zheng J, Wang W, et al. The anticancer effect of metformin combined with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer patients with or without type 2 diabetes mellitus: A systematic review and meta-analysis. Oncol Ther 2022; 10(2): 363-75.
[http://dx.doi.org/10.1007/s40487-022-00209-0] [PMID: 36282467]
[27]
Greene E, MacIver NJ. Targeting T cell (oxidative) metabolism to improve immunity to viral infection in the context of obesity. Front Immunol 2022; 13: 1025495.
[http://dx.doi.org/10.3389/fimmu.2022.1025495] [PMID: 36275776]
[28]
Qiao H, Li Y, Xu B, et al. Metformin can be safely used in patients exposed to contrast media: A systematic review and meta-analysis. Cardiology 2022; 147(5-6): 469-78.
[http://dx.doi.org/10.1159/000527384] [PMID: 36202076]
[29]
Mu W, Liang G, Yue Feng Y, Jiang Y, Qu F. The potential therapeutic role of metformin in diabetic and non-diabetic bone impairment. Pharmaceuticals 2022; 15(10): 1274.
[http://dx.doi.org/10.3390/ph15101274] [PMID: 36297386]
[30]
Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 2018; 17(1): 122.
[http://dx.doi.org/10.1186/s12933-018-0762-4] [PMID: 30170598]
[31]
Caturano A, Galiero R, Loffredo G, et al. Effects of a combination of empagliflozin plus metformin vs. Metformin monotherapy on nafld progression in type 2 diabetes: The IMAGIN pilot study. Biomedicines 2023; 11(2): 322.
[http://dx.doi.org/10.3390/biomedicines11020322] [PMID: 36830859]
[32]
Sikorskaya K, Zarzecka I, Ejikeme U, Russell J. The use of metformin as an add-on therapy to insulin in the treatment of poorly controlled type 1 diabetes mellitus in adolescents. Metabolism Open 2021; 9: 100080.
[http://dx.doi.org/10.1016/j.metop.2021.100080] [PMID: 33598651]
[33]
Bjornstad P, Schäfer M, Truong U, Melanie Cree-Green M, Laura Pyle L. Metformin improves insulin sensitivity and vascular health in youth with type 1 diabetes: A randomized control trial. Circulation 2018; 138(25): 2895-907.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.035525] [PMID: 30566007]
[34]
Coll AP, Chen M, Taskar P, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature 2020; 578(7795): 444-8.
[http://dx.doi.org/10.1038/s41586-019-1911-y] [PMID: 31875646]
[35]
Lunder M, Janić M, Japelj M, Juretič A, Janež A, Šabovič M. Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus. Cardiovasc Diabetol 2018; 17(1): 153.
[http://dx.doi.org/10.1186/s12933-018-0797-6] [PMID: 30509271]
[36]
Petrovic AR, Jovanovic IP, Jurisevic MM, et al. Metformin promotes antitumor activity of NK cells via overexpression of miRNA-150 and miRNA-155. Am J Transl Res 2023; 15(4): 2727-37.
[PMID: 37193182]
[37]
Lee DE, Lee GY, Lee HM, Choi SY, Lee SJ, Kwon OS. Synergistic apoptosis by combination of metformin and an O-GlcNAcylation inhibitor in colon cancer cells. Cancer Cell Int 2023; 23(1): 108.
[http://dx.doi.org/10.1186/s12935-023-02954-2] [PMID: 37268905]
[38]
Huang X, Sun T, Wang J, et al. Metformin reprograms tryptophan metabolism to stimulate CD8+ T cell function in colorectal cancer. Cancer Res 2023; 83(14): 2358-71.
[http://dx.doi.org/10.1158/0008-5472.CAN-22-3042] [PMID: 37195082]
[39]
Lv Z, Guo Y. Metformin and its benefits for various diseases. Front Endocrinol 2020; 11: 191.
[http://dx.doi.org/10.3389/fendo.2020.00191] [PMID: 32425881]
[40]
Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330(7503): 1304-5.
[http://dx.doi.org/10.1136/bmj.38415.708634.F7]
[41]
Zhao B, Luo J, Yu T, Zhou L, Lv H, Shang P. Anticancer mechanisms of metformin: A review of the current evidence. Life Sci 2020; 254: 117717.
[http://dx.doi.org/10.1016/j.lfs.2020.117717] [PMID: 32339541]
[42]
Hasanvand A. The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: A new perspective for treatment and prevention of diseases. Inflammopharmacology 2022; 30(3): 775-88.
[http://dx.doi.org/10.1007/s10787-022-00980-6] [PMID: 35419709]
[43]
DeCensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res 2010; 3(11): 1451-61.
[http://dx.doi.org/10.1158/1940-6207.CAPR-10-0157] [PMID: 20947488]
[44]
Podhorecka M, Ibanez B, Dmoszyńska A. Metformin - its potential anti-cancer and anti-aging effects. Postepy Hig Med Dosw 2017; 71(1): 0.
[http://dx.doi.org/10.5604/01.3001.0010.3801] [PMID: 28258677]
[45]
Luengo A, Sullivan LB, Heiden MGV. Understanding the complex-I-ty of metformin action: Limiting mitochondrial respiration to improve cancer therapy. BMC Biol 2014; 12(1): 82.
[http://dx.doi.org/10.1186/s12915-014-0082-4] [PMID: 25347702]
[46]
Hahn S, Oh BJ, Kim H, et al. Anti-cancer effects of metformin in a 3D co-culture model of pancreatic ductal adenocarcinoma. Am J Cancer Res 2023; 13(5): 1806-25.
[PMID: 37293149]
[47]
Saraei P, Asadi I, Kakar MA, Moradi-Kor N. The beneficial effects of metformin on cancer prevention and therapy: A comprehensive review of recent advances. Cancer Manag Res 2019; 11: 3295-313.
[http://dx.doi.org/10.2147/CMAR.S200059] [PMID: 31114366]
[48]
Yu H, Zhong X, Gao P, et al. The potential effect of metformin on cancer: An umbrella review. Front Endocrinol 2019; 2019: 00617.
[http://dx.doi.org/10.3389/fendo.2019.00617]
[49]
Kim HJ, Lee S, Chun KH, et al. Metformin reduces the risk of cancer in patients with type 2 diabetes. Medicine 2018; 97(8): e0036.
[http://dx.doi.org/10.1097/MD.0000000000010036] [PMID: 29465545]
[50]
Yoon WS, Chang JH, Kim JH, et al. Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: A randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study). Discov Oncol 2023; 14(1): 90.
[http://dx.doi.org/10.1007/s12672-023-00678-3] [PMID: 37278858]
[51]
Kennedy OJ, Kicinski M, Valpione S, et al. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer 2023; 29(23): S0959-49.
[http://dx.doi.org/10.1016/j.ejca.2023.04.016]
[52]
Vedire YR, Mukherjee S, Dondapati S, Yendamuri S. Association between visceral obesity, metformin use, and recurrence risk in early-stage colorectal cancer. Sci Rep 2023; 13(1): 8401.
[http://dx.doi.org/10.1038/s41598-023-34690-y] [PMID: 37225730]
[53]
Lai IL, You JF, Tsai WS, Hsu YJ, Chern YJ, Wu MY. Metformin increases pathological responses to rectal cancers with neoadjuvant chemoradiotherapy: A systematic review and meta-analysis. World J Surg Oncol 2023; 21(1): 224.
[http://dx.doi.org/10.1186/s12957-023-03087-6] [PMID: 37491250]
[54]
Delgado-Waldo I, Contreras-Romero C, Salazar-Aguilar S, et al. A triple-drug combination induces apoptosis in cervical cancer derived cell lines. Front Oncol 2023; 13: 1106667.
[http://dx.doi.org/10.3389/fonc.2023.1106667] [PMID: 37223676]
[55]
Cheng Y, Zhan P, Lu J, et al. Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT‐FOXO3 signalling pathway. Liver Int 2023; 43(7): 1577-92.
[http://dx.doi.org/10.1111/liv.15611] [PMID: 37208925]
[56]
Wilson BE, Armstrong AJ, de Bono J, et al. Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. Eur J Cancer 2022; 170: 296-304.
[http://dx.doi.org/10.1016/j.ejca.2022.03.042] [PMID: 35568679]
[57]
Skuli SJ, Alomari S, Gaitsch H, Bakayoko A, Skuli N, Tyler BM. Metformin and cancer, an ambiguanidous relationship. Pharmaceuticals 2022; 15(5): 626.
[http://dx.doi.org/10.3390/ph15050626] [PMID: 35631452]
[58]
Hsu Y, Hsu CY, Kao YS. The association between metformin and the cancer-specific mortality rate in nasopharyngeal cancer patients: Real-world evidence. Curr Oncol 2023; 30(4): 3940-50.
[http://dx.doi.org/10.3390/curroncol30040298] [PMID: 37185411]
[59]
Chen CJ, Huang JY, Huang JQ, et al. Metformin attenuates multiple myeloma cell proliferation and encourages apoptosis by suppressing METTL3-mediated m6A methylation of THRAP3, RBM25, and USP4. Cell Cycle 2023; 22(8): 986-1004.
[http://dx.doi.org/10.1080/15384101.2023.2170521] [PMID: 36762777]
[60]
Brown RJ, Araujo-Vilar D, Cheung PT, et al. The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline. J Clin Endocrinol Metab 2016; 101(12): 4500-11.
[http://dx.doi.org/10.1210/jc.2016-2466] [PMID: 27710244]
[61]
Li Y, Zhang Q, Yang J, et al. Metformin combined with glucose starvation synergistically suppress triple-negative breast cancer by enhanced unfolded protein response. Biochem Biophys Res Commun 2023; 675: 146-54.
[http://dx.doi.org/10.1016/j.bbrc.2023.07.029] [PMID: 37473529]
[62]
Chen S, Zhou J, Xi M, et al. Pharmacogenetic variation and metformin response. Curr Drug Metab 2013; 14(10): 1070-82.
[http://dx.doi.org/10.2174/1389200214666131211153933] [PMID: 24329113]
[63]
Hua Y, Zheng Y, Yao Y, Jia R, Ge S, Zhuang A. Metformin and cancer hallmarks: Shedding new lights on therapeutic repurposing. J Transl Med 2023; 21(1): 403.
[http://dx.doi.org/10.1186/s12967-023-04263-8] [PMID: 37344841]
[64]
Yang D, Zhao F, Su Y, et al. Analysis of M2 macrophage associated risk score signature in pancreatic cancer TME landscape and immunotherapy. Front Mol Biosci 2023; 10: 1184708.
[http://dx.doi.org/10.3389/fmolb.2023.1184708] [PMID: 37469705]
[65]
Yadav P, Makwana S, Bansal S, et al. Metformin prevents osteoblast‐ like potential and calcification in lung cancer A549 cells. J Biochem Mol Toxicol 2023; e23454: e23454.
[http://dx.doi.org/10.1002/jbt.23454] [PMID: 37409753]
[66]
Barrios-Bernal P, Hernández-Pedro N, Lara-Mejía L, Arrieta O. Obesity paradox and lung cancer, metformin-based therapeutic opportunity? Oncotarget 2023; 14(1): 670-1.
[http://dx.doi.org/10.18632/oncotarget.28432] [PMID: 37395790]
[67]
Burt HJ, Neuhoff S, Almond L, et al. Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions. Eur J Pharm Sci 2016; 88(10): 70-82.
[http://dx.doi.org/10.1016/j.ejps.2016.03.020] [PMID: 27019345]
[68]
Nathwani N, Palmer J, Synold TW, et al. Toxicities associated with metformin/ritonavir combination treatment in relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2020; 20(10): e667-72.
[http://dx.doi.org/10.1016/j.clml.2020.05.017]
[69]
Li M, Li X, Zhang H, Lu Y. Molecular mechanisms of metformin for diabetes and cancer treatment. Front Physiol 2018; 9: 1039.
[http://dx.doi.org/10.3389/fphys.2018.01039] [PMID: 30108523]
[70]
Le A, Udupa S, Zhang C. The metabolic interplay between cancer and other diseases. Trends Cancer 2019; 5(12): 809-21.
[http://dx.doi.org/10.1016/j.trecan.2019.10.012] [PMID: 31813458]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy